

6. Literature

1. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. *N Engl J Med* 348:138.
2. Wheeler, A. P., and G. R. Bernard. 1999. Treating patients with severe sepsis. *N Engl J Med* 340:207.
3. Angus, D. C., and R. S. Wax. 2001. Epidemiology of sepsis: an update. *Crit Care Med* 29:S109.
4. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 29:1303.
5. Stone, R. 1994. Search for sepsis drugs goes on despite past failures. *Science* 264:365.
6. Parrillo, J. E., M. M. Parker, C. Natanson, A. F. Suffredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. *Ann Intern Med* 113:227.
7. Baue, A. E. 1997. Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? *Arch Surg* 132:703.
8. Zeni, F., B. Freeman, and C. Natanson. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. *Crit Care Med* 25:1095.
9. Abraham, E. 1999. Why immunomodulatory therapies have not worked in sepsis. *Intensive Care Med* 25:556.
10. Bone, R. C. 1995. Sepsis and controlled clinical trials: the odyssey continues. *Crit Care Med* 23:1313.
11. Fry, D. E. 2000. Sepsis syndrome. *Am Surg* 66:126.
12. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2001. Sepsis syndromes: understanding the role of innate and acquired immunity. *Shock* 16:83.
13. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 20:864.
14. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2000. Cytokine signaling--regulation of the immune response in normal and critically ill states. *Crit Care Med* 28:N3.
15. Bone, R. C. 1996. Sir Isaac Newton, sepsis, SIRS, and CARS. *Crit Care Med* 24:1125.
16. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. *Science* 272:50.
17. Janeway, C. A., Jr. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. *Immunol Today* 13:11.

18. Matzinger, P. 1994. Tolerance, danger, and the extended family. *Annu Rev Immunol* 12:991.
19. Bendelac, A., and D. T. Fearon. 1997. Innate pathways that control acquired immunity. *Curr Opin Immunol* 9:1.
20. Ezekowitz, R. A. B., and J. A. Hoffmann. 1996. Innate immunity. *Curr Opin Immunol* 8:1.
21. Janeway, C. A., Jr. 2001. How the immune system works to protect the host from infection: a personal view. *Proc Natl Acad Sci U S A* 98:7461.
22. Janeway, C. A., Jr. 2001. How the immune system protects the host from infection. *Microbes Infect* 3:1167.
23. Ksontini, R., S. L. MacKay, and L. L. Moldawer. 1998. Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. *Arch Surg* 133:558.
24. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, R. E. Schmiegl, Jr., J. J. Hui, K. C. Chang, D. F. Osborne, B. D. Freeman, J. P. Cobb, T. G. Buchman, and I. E. Karl. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. *J Immunol* 166:6952.
25. Ertel, W., J. P. Kremer, J. Kenney, U. Steckholzer, D. Jarrar, O. Trentz, and F. W. Schildberg. 1995. Downregulation of proinflammatory cytokine release in whole blood from septic patients. *Blood* 85:1341.
26. Alexander, H. R., G. M. Doherty, M. I. Block, P. J. Kragel, J. C. Jensen, H. N. Langstein, E. Walker, and J. A. Norton. 1991. Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. *Infect Immun* 59:3889.
27. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J Immunol* 151:1548.
28. McNamara, M. J., J. A. Norton, R. J. Nauta, and H. R. Alexander. 1993. Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. *J Surg Res* 54:316.
29. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. *J Exp Med* 177:1205.
30. O'Riordain, M. G., D. S. O'Riordain, R. G. Molloy, J. A. Mannick, and M. L. Rodrick. 1996. Dosage and timing of anti-TNF-alpha antibody treatment determine its effect of resistance to sepsis after injury. *J Surg Res* 64:95.
31. Remick, D., P. Manohar, G. Bolgos, J. Rodriguez, L. Moldawer, and G. Wollenberg. 1995. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. *Shock* 4:89.

32. Fukuzuka, K., J. J. Rosenberg, G. C. Gaines, C. K. Edwards, 3rd, M. Clare-Salzler, S. L. MacKay, L. L. Moldawer, E. M. Copeland, 3rd, and D. W. Mazingo. 1999. Caspase-3-dependent organ apoptosis early after burn injury. *Ann Surg* 229:851.
33. Hotchkiss, R. S., P. E. Swanson, J. P. Cobb, A. Jacobson, T. G. Buchman, and I. E. Karl. 1997. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. *Crit Care Med* 25:1298.
34. Ayala, A., C. D. Herdon, D. L. Lehman, C. A. Ayala, and I. H. Chaudry. 1996. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. *Blood* 87:4261.
35. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, K. C. Chang, J. P. Cobb, T. G. Buchman, S. J. Korsmeyer, and I. E. Karl. 1999. Prevention of lymphocyte cell death in sepsis improves survival in mice. *Proc Natl Acad Sci U S A* 96:14541.
36. Hotchkiss, R. S., P. E. Swanson, B. D. Freeman, K. W. Tinsley, J. P. Cobb, G. M. Matuschak, T. G. Buchman, and I. E. Karl. 1999. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med* 27:1230.
37. Tinsley, K. W., S. L. Cheng, T. G. Buchman, K. C. Chang, J. J. Hui, P. E. Swanson, I. E. Karl, and R. S. Hotchkiss. 2000. Caspases -2, -3, -6, and -9, but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. *Shock* 13:1.
38. Hakem, R., A. Hakem, G. S. Duncan, J. T. Henderson, M. Woo, M. S. Soengas, A. Elia, J. L. de la Pompa, D. Kagi, W. Khoo, J. Potter, R. Yoshida, S. A. Kaufman, S. W. Lowe, J. M. Penninger, and T. W. Mak. 1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. *Cell* 94:339.
39. Ayala, A., C. S. Chung, Y. X. Xu, T. A. Evans, K. M. Redmond, and I. H. Chaudry. 1999. Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin. *Immunology* 97:45.
40. Casey, L. C., R. A. Balk, and R. C. Bone. 1993. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. *Ann Intern Med* 119:771.
41. Marano, M. A., L. L. Moldawer, Y. Fong, H. Wei, J. Minei, R. Yurt, A. Cerami, and S. F. Lowry. 1988. Cachectin/TNF production in experimental burns and *Pseudomonas* infection. *Arch Surg* 123:1383.
42. Schein, R. M., C. L. Sprung, E. Marcial, L. Napolitano, and B. Chernow. 1990. Plasma cortisol levels in patients with septic shock. *Crit Care Med* 18:259.
43. Dibbert, B., M. Weber, W. H. Nikolaizik, P. Vogt, M. H. Schoni, K. Blaser, and H. U. Simon. 1999. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. *Proc Natl Acad Sci U S A* 96:13330.

44. Menges, T., J. Engel, I. Welters, R. M. Wagner, S. Little, R. Ruwoldt, M. Wollbrueck, and G. Hempelmann. 1999. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. *Crit Care Med* 27:733.
45. Cheadle, W. G., R. M. Pemberton, D. Robinson, D. H. Livingston, J. L. Rodriguez, and H. C. Polk, Jr. 1993. Lymphocyte subset responses to trauma and sepsis. *J Trauma* 35:844.
46. Hiramatsu, M., R. S. Hotchkiss, I. E. Karl, and T. G. Buchman. 1997. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. *Shock* 7:247.
47. Keel, M., N. Schreggenberger, U. Steckholzer, U. Ungethum, J. Kenney, O. Trentz, and W. Ertel. 1996. Endotoxin tolerance after severe injury and its regulatory mechanisms. *J Trauma* 41:430.
48. Faist, E., A. Mewes, T. Strasser, A. Walz, S. Alkan, C. Baker, W. Ertel, and G. Heberer. 1988. Alteration of monocyte function following major injury. *Arch Surg* 123:287.
49. O'Sullivan, S. T., J. A. Lederer, A. F. Horgan, D. H. Chin, J. A. Mannick, and M. L. Rodrick. 1995. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. *Ann Surg* 222:482.
50. Weiss, S. J. 1989. Tissue destruction by neutrophils. *N Engl J Med* 320:365.
51. Doherty, D. E., G. P. Downey, G. S. Worthen, C. Haslett, and P. M. Henson. 1988. Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils. *Lab Invest* 59:200.
52. Botha, A. J., F. A. Moore, E. E. Moore, F. J. Kim, A. Banerjee, and V. M. Peterson. 1995. Postinjury neutrophil priming and activation: an early vulnerable window. *Surgery* 118:358.
53. Simms, H. H., and R. D'Amico. 1994. Polymorphonuclear leukocyte dysregulation during the systemic inflammatory response syndrome. *Blood* 83:1398.
54. Vartio, T., H. Seppa, and A. Vaheri. 1981. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. *J Biol Chem* 256:471.
55. Squier, M. K., A. J. Sehnert, and J. J. Cohen. 1995. Apoptosis in leukocytes. *J Leukoc Biol* 57:2.
56. Thompson, C. B. 1995. Apoptosis in the pathogenesis and treatment of disease. *Science* 267:1456.
57. Kroemer, G., P. Petit, N. Zamzami, J. L. Vayssiere, and B. Mignotte. 1995. The biochemistry of programmed cell death. *Faseb J* 9:1277.
58. Nagata, S. 1997. Apoptosis by death factor. *Cell* 88:355.

59. Hale, A. J., C. A. Smith, L. C. Sutherland, V. E. Stoneman, V. L. Longthorne, A. C. Culhane, and G. T. Williams. 1996. Apoptosis: molecular regulation of cell death. *Eur J Biochem* 236:1.
60. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell* 75:1169.
61. Suda, T., and S. Nagata. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. *J Exp Med* 179:873.
62. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). *Nature* 373:438.
63. Kiener, P. A., P. M. Davis, G. C. Starling, C. Mehlin, S. J. Klebanoff, J. A. Ledbetter, and W. C. Liles. 1997. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. *J Exp Med* 185:1511.
64. Broome, H. E., C. M. Dargan, S. Krajewski, and J. C. Reed. 1995. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. *J Immunol* 155:2311.
65. Duke, R. C., and J. J. Cohen. 1986. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. *Lymphokine Res* 5:289.
66. Hotchkiss, R. S., and I. E. Karl. 2001. The Fas death pathway as a mechanism of multiple organ dysfunction syndrome: not so fast. *Crit Care Med* 29:901.
67. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, M. H. Grayson, D. F. Osborne, T. H. Wagner, J. P. Cobb, C. Coopersmith, and I. E. Karl. 2002. Depletion of dendritic cells, but not macrophages, in patients with sepsis. *J Immunol* 168:2493.
68. Savill, J., V. Fadok, P. Henson, and C. Haslett. 1993. Phagocyte recognition of cells undergoing apoptosis. *Immunol Today* 14:131.
69. Ertel, W., M. Keel, M. Infanger, U. Ungethum, U. Steckholzer, and O. Trentz. 1998. Circulating mediators in serum of injured patients with septic complications inhibit neutrophil apoptosis through up-regulation of protein-tyrosine phosphorylation. *J Trauma* 44:767.
70. Keel, M., U. Ungethum, U. Steckholzer, E. Niederer, T. Hartung, O. Trentz, and W. Ertel. 1997. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. *Blood* 90:3356.
71. Hotchkiss, R. S., P. E. Swanson, C. M. Knudson, K. C. Chang, J. P. Cobb, D. F. Osborne, K. M. Zollner, T. G. Buchman, S. J. Korsmeyer, and I. E. Karl. 1999. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. *J Immunol* 162:4148.
72. Coopersmith, C. M., D. O'Donnell, and J. I. Gordon. 1999. Bcl-2 inhibits ischemia-reperfusion-induced apoptosis in the intestinal epithelium of transgenic mice. *Am J Physiol* 276:G677.

73. Arai, K. I., F. Lee, A. Miyajima, S. Miyatake, N. Arai, and T. Yokota. 1990. Cytokines: coordinators of immune and inflammatory responses. *Annu Rev Biochem* 59:783.
74. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7:145.
75. Constant, S. L., and K. Bottomly. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. *Annu Rev Immunol* 15:297.
76. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392:245.
77. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. *Annu Rev Immunol* 18:593.
78. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. *Annu Rev Immunol* 18:767.
79. Crystal, R. G. 1995. The gene as the drug. *Nat Med* 1:15.
80. Crystal, R. G., A. Jaffe, S. Brody, A. Mastrangeli, N. G. McElvaney, M. Rosenfeld, C. S. Chu, C. Danel, J. Hay, and T. Eissa. 1995. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. *Hum Gene Ther* 6:643.
81. Crystal, R. G. 1995. Transfer of genes to humans: early lessons and obstacles to success. *Science* 270:404.
82. Anderson, W. F. 1998. Human gene therapy. *Nature* 392:25.
83. Blaese, R. M. 1997. Gene therapy for cancer. *Sci Am* 276:111.
84. Brigham, K. L., A. E. Canonico, B. O. Meyrick, H. Schreier, A. A. Stecenko, and J. T. Conary. 1994. Gene therapy for inflammatory diseases. *Prog Clin Biol Res* 388:361.
85. Favrot, M. C. 1998. Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII. *Therapie* 53:381.
86. Nevin, N. C., and J. Spink. 2000. Gene therapy advisory committee: long-term monitoring of patients participating in gene therapy: Health Departments of the United Kingdom. *Hum Gene Ther* 11:1253.
87. Pilaro, A. M., and M. A. Serabian. 1999. Preclinical development strategies for novel gene therapeutic products. *Toxicol Pathol* 27:4.
88. Roth, J. A., and R. J. Cristiano. 1997. Gene therapy for cancer: what have we done and where are we going? *J Natl Cancer Inst* 89:21.

89. Canonico, A. E., J. D. Plitman, J. T. Conary, B. O. Meyrick, and K. L. Brigham. 1994. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes. *J Appl Physiol* 77:415.
90. Crystal, R. G., N. G. McElvaney, M. A. Rosenfeld, C. S. Chu, A. Mastrangeli, J. G. Hay, S. L. Brody, H. A. Jaffe, N. T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. *Nat Genet* 8:42.
91. Huard, J., H. Lochmuller, G. Acsadi, A. Jani, B. Massie, and G. Karpati. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. *Gene Ther* 2:107.
92. Nielsen, L. L., M. Gurnani, J. Syed, J. Dell, B. Hartman, M. Cartwright, and R. C. Johnson. 1998. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. *Hum Gene Ther* 9:681.
93. Massie, B., F. Couture, L. Lamoureux, D. D. Mosser, C. Guilbault, P. Jolicoeur, F. Belanger, and Y. Langelier. 1998. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. *J Virol* 72:2289.
94. No, D., T. P. Yao, and R. M. Evans. 1996. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. *Proc Natl Acad Sci U S A* 93:3346.
95. Knowles, M. R., P. G. Noone, K. Hohneker, L. G. Johnson, R. C. Boucher, J. Efthimiou, C. Crawford, R. Brown, C. Schwartzbach, and R. Pearlman. 1998. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. *Hum Gene Ther* 9:249.
96. Zhang, H. G., T. Zhou, P. Yang, C. K. Edwards, 3rd, D. T. Curiel, and J. D. Mountz. 1998. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. *Hum Gene Ther* 9:1875.
97. Minter, R. M., J. E. Rectenwald, K. Fukuzuka, C. L. Tannahill, D. La Face, V. Tsai, I. Ahmed, E. Hutchins, R. Moyer, E. M. Copeland, 3rd, and L. L. Moldawer. 2000. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. *J Immunol* 164:443.
98. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. *Hum Gene Ther* 8:37.
99. Li, Q., M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet, and S. L. Woo. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. *Hum Gene Ther* 4:403.
100. Elkon, K. B., C. C. Liu, J. G. Gall, J. Trevejo, M. W. Marino, K. A. Abrahamsen, X. Song, J. L. Zhou, L. J. Old, R. G. Crystal, and E. Falck-Pedersen. 1997.

- Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. *Proc Natl Acad Sci U S A* 94:9814.
101. Bett, A. J., L. Prevec, and F. L. Graham. 1993. Packaging capacity and stability of human adenovirus type 5 vectors. *J Virol* 67:5911.
 102. Romano, G., C. Pacilio, and A. Giordano. 1999. Gene transfer technology in therapy: current applications and future goals. *Stem Cells* 17:191.
 103. Engelhardt, J. F., Y. Yang, L. D. Stratford-Perricaudet, E. D. Allen, K. Kozarsky, M. Perricaudet, J. R. Yankaskas, and J. M. Wilson. 1993. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. *Nat Genet* 4:27.
 104. Ferry, N., and J. M. Heard. 1998. Liver-directed gene transfer vectors. *Hum Gene Ther* 9:1975.
 105. Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc Natl Acad Sci U S A* 93:13565.
 106. Fisher, K. J., H. Choi, J. Burda, S. J. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. *Virology* 217:11.
 107. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. *J Virol* 70:8934.
 108. Oberholzer, A., M. Keel, R. Zellweger, U. Steckholzer, O. Trentz, and W. Ertel. 2000. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. *J Trauma* 48:932.
 109. Ertel, W., A. Oberholzer, A. Platz, R. Stocker, and O. Trentz. 2000. Incidence and clinical pattern of the abdominal compartment syndrome after "damage-control" laparotomy in 311 patients with severe abdominal and/or pelvic trauma. *Crit Care Med* 28:1747.
 110. Oberholzer, A., A. Feilner, H. Hentze, U. Steckholzer, M. Kurimoto, O. Trentz, and W. Ertel. 2000. Sepsis after severe injury interrupts caspase-dependent processing of interleukin-18. *J Trauma* 49:11.
 111. Oberholzer, A., L. Harter, A. Feilner, U. Steckholzer, O. Trentz, and W. Ertel. 2000. Differential effect of caspase inhibition on proinflammatory cytokine release in septic patients. *Shock* 14:253.
 112. Oberholzer, A., U. Steckholzer, M. Kurimoto, O. Trentz, and W. Ertel. 2001. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. *Shock* 16:411.
 113. Feezor, R. J., C. Oberholzer, H. V. Baker, D. Novick, M. Rubinstein, L. L. Moldawer, J. Pribble, S. Souza, C. A. Dinarello, W. Ertel, and A. Oberholzer. 2003. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. *Infect Immun* 71:5803.

114. Oberholzer, C., A. Oberholzer, F. R. Bahjat, R. M. Minter, C. L. Tannahill, A. Abouhamze, D. LaFace, B. Hutchins, M. J. Clare-Salzler, and L. L. Moldawer. 2001. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. *Proc Natl Acad Sci U S A* 98:11503.
115. Minter, R. M., M. A. Ferry, M. E. Murday, C. L. Tannahill, F. R. Bahjat, C. Oberholzer, A. Oberholzer, D. LaFace, B. Hutchins, S. Wen, J. Shinoda, E. M. Copeland, 3rd, and L. L. Moldawer. 2001. Adenoviral delivery of human and viral IL-10 in murine sepsis. *J Immunol* 167:1053.
116. Minter, R. M., M. A. Ferry, J. E. Rectenwald, F. R. Bahjat, A. Oberholzer, C. Oberholzer, D. LaFace, V. Tsai, C. M. Ahmed, B. Hutchins, E. M. Copeland, 3rd, H. S. Ginsberg, and L. L. Moldawer. 2001. Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. *Proc Natl Acad Sci U S A* 98:277.
117. Oberholzer, A., C. Oberholzer, K. S. Bahjat, R. Ungaro, C. L. Tannahill, M. Murday, F. R. Bahjat, Z. Abouhamze, V. Tsai, D. LaFace, B. Hutchins, L. L. Moldawer, and M. J. Clare-Salzler. 2002. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. *J Immunol* 168:3412.
118. Smith, R. C., K. N. Wills, D. Antelman, H. Perlman, L. N. Truong, K. Krasinski, and K. Walsh. 1997. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. *Circulation* 96:1899.
119. Wills, K. N., D. C. Maneval, P. Menzel, M. P. Harris, S. Sutjipto, M. T. Vaillancourt, W. M. Huang, D. E. Johnson, S. C. Anderson, S. F. Wen, and et al. 1994. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. *Hum Gene Ther* 5:1079.
120. Graham, F. L., and L. Prevec. 1995. Methods for construction of adenovirus vectors. *Mol Biotechnol* 3:207.
121. Baker, C. C., I. H. Chaudry, H. O. Gaines, and A. E. Baue. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. *Surgery* 94:331.
122. Salomon, B., J. L. Cohen, C. Masurier, and D. Klatzmann. 1998. Three populations of mouse lymph node dendritic cells with different origins and dynamics. *J Immunol* 160:708.
123. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J Immunol Methods* 95:99.
124. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* 176:1693.

125. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. *J Exp Med* 182:389.
126. Bell, D., J. W. Young, and J. Banchereau. 1999. Dendritic cells. *Adv Immunol* 72:255.
127. Tuting, T., J. Steitz, J. Bruck, A. Gambotto, K. Steinbrink, A. B. DeLeo, P. Robbins, J. Knop, and A. H. Enk. 1999. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. *J Gene Med* 1:400.
128. Ribas, A., L. H. Butterfield, W. H. McBride, S. M. Jilani, L. A. Bui, C. M. Vollmer, R. Lau, V. B. Dissette, B. Hu, A. Y. Chen, J. A. Glaspy, and J. S. Economou. 1997. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. *Cancer Res* 57:2865.
129. Song, W., H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. *J Exp Med* 186:1247.
130. Song, W., H. L. Kong, P. Traktman, and R. G. Crystal. 1997. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. *Hum Gene Ther* 8:1207.
131. Chen, P. W., M. Wang, V. Bronte, Y. Zhai, S. A. Rosenberg, and N. P. Restifo. 1996. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. *J Immunol* 156:224.
132. Takayama, T., Y. Nishioka, L. Lu, M. T. Lotze, H. Tahara, and A. W. Thomson. 1998. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. *Transplantation* 66:1567.
133. Furumoto, K., S. Arai, S. Yamasaki, M. Mizumoto, A. Mori, N. Inoue, N. Isobe, and M. Imamura. 2000. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. *Int J Cancer* 87:665.
134. Ardavin, C. 1997. Thymic dendritic cells. *Immunol Today* 18:350.
135. Kaplan, J. M., Q. Yu, S. T. Piraino, S. E. Pennington, S. Shankara, L. A. Woodworth, and B. L. Roberts. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. *J Immunol* 163:699.
136. Rea, D., F. H. Schagen, R. C. Hoeben, M. Mehtali, M. J. Havenga, R. E. Toes, C. J. Melief, and R. Offringa. 1999. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. *J Virol* 73:10245.

137. Linette, G. P., S. Shankara, S. Longerich, S. Yang, R. Doll, C. Nicolette, F. I. Preffer, B. L. Roberts, and F. G. Haluska. 2000. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. *J Immunol* 164:3402.
138. Peeters, M. J., G. A. Patijn, A. Lieber, L. Meuse, and M. A. Kay. 1996. Adenovirus-mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. *Hum Gene Ther* 7:1693.
139. Muruve, D. A., M. J. Barnes, I. E. Stillman, and T. A. Libermann. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. *Hum Gene Ther* 10:965.
140. Lieber, A., C. Y. He, L. Meuse, D. Schowalter, I. Kirillova, B. Winther, and M. A. Kay. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. *J Virol* 71:8798.
141. Gorczynski, R. M., J. Bransom, M. Cattral, X. Huang, J. Lei, L. Xiaorong, W. P. Min, Y. Wan, and J. Gauldie. 2000. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. *Clin Immunol* 95:182.
142. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. *J Immunol* 158:3270.
143. Melero, I., M. Duarte, J. Ruiz, B. Sangro, J. Galofre, G. Mazzolini, M. Bustos, C. Qian, and J. Prieto. 1999. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. *Gene Ther* 6:1779.
144. Shortman, K., D. Vremec, L. M. Corcoran, K. Georgopoulos, K. Lucas, and L. Wu. 1998. The linkage between T-cell and dendritic cell development in the mouse thymus. *Immunol Rev* 165:39.
145. Christ, M., M. Lusky, F. Stoeckel, D. Dreyer, A. Dieterle, A. I. Michou, A. Pavirani, and M. Mehtali. 1997. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. *Immunol Lett* 57:19.
146. Biron, C. A. 1994. Cytokines in the generation of immune responses to, and resolution of, virus infection. *Curr Opin Immunol* 6:530.
147. Abraham, E., A. Anzueto, G. Gutierrez, S. Tessler, G. San Pedro, R. Wunderink, A. Dal Nogare, S. Nasraway, S. Berman, R. Cooney, H. Levy, R. Baughman, M. Rumbak, R. B. Light, L. Poole, R. Allred, J. Constant, J. Pennington, and S. Porter. 1998. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. *Lancet* 351:929.

148. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, and et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. *Jama* 271:1836.
149. Oberholzer, C., A. Oberholzer, M. Clare-Salzler, and L. L. Moldawer. 2001. Apoptosis in sepsis: a new target for therapeutic exploration. *Faseb J* 15:879.
150. Fukuzuka, K., C. K. Edwards, 3rd, M. Clare-Salzler, E. M. Copeland, 3rd, L. L. Moldawer, and D. W. Mozingo. 2000. Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. *Am J Physiol Regul Integr Comp Physiol* 278:R1005.
151. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. *Nature* 377:348.
152. Cohen, S. B., J. B. Crawley, M. C. Kahan, M. Feldmann, and B. M. Foxwell. 1997. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. *Immunology* 92:1.
153. Gross, A., J. Jockel, M. C. Wei, and S. J. Korsmeyer. 1998. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. *Embo J* 17:3878.
154. Levy, Y., and J. C. Brouet. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. *J Clin Invest* 93:424.
155. Docke, W. D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H. D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. *Nat Med* 3:678.
156. Eskandari, M. K., G. Bolgos, C. Miller, D. T. Nguyen, L. E. DeForge, and D. G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. *J Immunol* 148:2724.
157. Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, V. Joulin, and A. Kahn. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. *Nat Med* 2:80.
158. Strasser, A., A. W. Harris, and S. Cory. 1991. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. *Cell* 67:889.
159. Yin, X. M., K. Wang, A. Gross, Y. Zhao, S. Zinkel, B. Klocke, K. A. Roth, and S. J. Korsmeyer. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. *Nature* 400:886.
160. Zha, H., C. Aime-Sempe, T. Sato, and J. C. Reed. 1996. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. *J Biol Chem* 271:7440.

161. Taga, K., B. Cherney, and G. Tosato. 1993. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. *Int Immunol* 5:1599.
162. Deitch, E. A. 1998. Animal models of sepsis and shock: a review and lessons learned. *Shock* 9:1.
163. Remick, D. G., S. J. Garg, D. E. Newcomb, G. Wollenberg, T. K. Huie, and G. L. Bolgos. 1998. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. *Crit Care Med* 26:895.
164. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 9:271.
165. Pulendran, B., K. Palucka, and J. Banchereau. 2001. Sensing pathogens and tuning immune responses. *Science* 293:253.
166. Reis e Sousa, C. 2001. Dendritic cells as sensors of infection. *Immunity* 14:495.
167. Oberholzer, A., C. Oberholzer, R. M. Minter, and L. L. Moldawer. 2001. Considering immunomodulatory therapies in the septic patient: should apoptosis be a potential therapeutic target? *Immunol Lett* 75:221.
168. Karp, C. L., M. Wysocka, X. Ma, M. Marovich, R. E. Factor, T. Nutman, M. Armant, L. Wahl, P. Cuomo, and G. Trinchieri. 1998. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. *Eur J Immunol* 28:3128.
169. Wysocka, M., S. Robertson, H. Riemann, J. Caamano, C. Hunter, A. Mackiewicz, L. J. Montaner, G. Trinchieri, and C. L. Karp. 2001. IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. *J Immunol* 166:7504.
170. Faulkner, L., G. Buchan, and M. Baird. 2000. Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. *Immunology* 99:523.
171. De Smedt, T., M. Van Mechelen, G. De Becker, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. *Eur J Immunol* 27:1229.
172. Corinti, S., C. Albanesi, A. Ia Sala, S. Pastore, and G. Girolomoni. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. *J Immunol* 166:4312.
173. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. *Eur J Immunol* 29:964.
174. Morelli, A. E., A. T. Larregina, R. W. Ganster, A. F. Zahorchak, J. M. Plowey, T. Takayama, A. J. Logar, P. D. Robbins, L. D. Falo, and A. W. Thomson. 2000. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. *J Virol* 74:9617.
175. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 19:683.

176. Steinhauser, M. L., C. M. Hogaboam, S. L. Kunkel, N. W. Lukacs, R. M. Strieter, and T. J. Standiford. 1999. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. *J Immunol* 162:392.
177. Damas, P., A. Reuter, P. Gysen, J. Demonty, M. Lamy, and P. Franchimont. 1989. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. *Crit Care Med* 17:975.
178. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, M. Albert, N. Bhardwaj, I. Mellman, and R. M. Steinman. 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. *J Exp Med* 188:2163.
179. Steinbrink, K., M. Wolf, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. *J Immunol* 159:4772.
180. van der Poll, T., A. Marchant, C. V. Keogh, M. Goldman, and S. F. Lowry. 1996. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. *J Infect Dis* 174:994.
181. Neidhardt, R., M. Keel, U. Steckholzer, A. Safret, U. Ungethuen, O. Trentz, and W. Ertel. 1997. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. *J Trauma* 42:863.
182. Lyons, A., J. L. Kelly, M. L. Rodrick, J. A. Mannick, and J. A. Lederer. 1997. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. *Ann Surg* 226:450.
183. Yang, J. S., L. Y. Xu, Y. M. Huang, P. H. Van Der Meide, H. Link, and B. G. Xiao. 2000. Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. *Immunology* 101:397.
184. Takayama, T., A. E. Morelli, N. Onai, M. Hirao, K. Matsushima, H. Tahara, and A. W. Thomson. 2001. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. *J Immunol* 166:7136.
185. D'Amico, G., G. Frascaroli, G. Bianchi, P. Transidico, A. Doni, A. Vecchi, S. Sozzani, P. Allavena, and A. Mantovani. 2000. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. *Nat Immunol* 1:387.
186. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. *J Exp Med* 184:741.
187. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. *J Exp Med* 180:1263.

188. Arthur, J. F., L. H. Butterfield, M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. *Cancer Gene Ther* 4:17.
189. Dietz, A. B., and S. Vuk-Pavlovic. 1998. High efficiency adenovirus-mediated gene transfer to human dendritic cells. *Blood* 91:392.
190. Caux, C., C. Massacrier, B. Vanbervliet, C. Barthelemy, Y. J. Liu, and J. Banchereau. 1994. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. *Int Immunol* 6:1177.
191. Morel, A. S., S. Quaratino, D. C. Douek, and M. Londei. 1997. Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. *Eur J Immunol* 27:26.
192. Akbari, O., R. H. DeKruyff, and D. T. Umetsu. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. *Nat Immunol* 2:725.
193. Heufler, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G. Trinchieri, A. Enk, R. M. Steinman, N. Romani, and G. Schuler. 1996. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. *Eur J Immunol* 26:659.
194. Ma, X., A. D'Andrea, M. Kubin, M. Aste-Amezaga, A. Sartori, J. Monteiro, L. Showe, M. Wysocka, and G. Trinchieri. 1995. Production of interleukin-12. *Res Immunol* 146:432.
195. Macatonia, S. E., N. A. Hosken, M. Litton, P. Vieira, C. S. Hsieh, J. A. Culpepper, M. Wysocka, G. Trinchieri, K. M. Murphy, and A. O'Garra. 1995. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. *J Immunol* 154:5071.
196. Clare-Salzler, M. J., J. Brooks, A. Chai, K. Van Herle, and C. Anderson. 1992. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. *J Clin Invest* 90:741.
197. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. *J Exp Med* 174:915.
198. Hirschowitz, E. A., J. D. Weaver, G. E. Hidalgo, and D. E. Doherty. 2000. Murine dendritic cells infected with adenovirus vectors show signs of activation. *Gene Ther* 7:1112.
199. Kalinski, P., J. H. Schuitemaker, C. M. Hilkens, and M. L. Kapsenberg. 1998. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. *J Immunol* 161:2804.

200. Lee, W. C., S. Qiani, Y. Wan, W. Li, Z. Xing, J. Gauldie, J. J. Fung, A. W. Thomson, and L. Lu. 2000. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. *Immunology* 101:233.
201. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. *J Exp Med* 192:1213.
202. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* 389:737.
203. Wakkach, A., F. Cottrez, and H. Groux. 2000. Can interleukin-10 be used as a true immunoregulatory cytokine? *Eur Cytokine Netw* 11:153.